Stefan Mileschin

Moderna has injected its mRNA-derived vaccine for the seasonal flu into a human volunteer for the first time as part of a Phase 1/2 clinical study, the company announced on Wednesday.

This is a very early test for the new vaccine technology, geared primarily towards building a baseline understanding of the treatment's "safety, reactogenicity and immunogenicity," according to a Moderna release. mRNA-1010, as the vaccine has been dubbed, is designed to be effective against the four most common strains of the virus including, A H1N1, H3N2, influenza B Yamagata and influenza B Victoria.

https://www.engadget.com/moderna-sub...3.html?src=rss